Gilead Sciences, Inc. vs ZIM Integrated Shipping Services Ltd — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while ZIM Integrated Shipping Services Ltd trades at $29.99 (market cap $3.65B). The key difference: Gilead Sciences, Inc. is far larger — about 50× ZIM Integrated Shipping Services Ltd's market cap, and ZIM Integrated Shipping Services Ltd pays the higher dividend (20.16%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and ZIM Integrated Shipping Services Ltd for 27 Days on average.
| GILD | ZIM | |
|---|---|---|
Market Cap | $182.40B | $3.65B |
Volume | 4,469,821 | 1,068,475 |
Sector | Health | Industrials |
52-Week High | $155.80 | $30.51 |
52-Week Low | $116.74 | $12.44 |
Typical Hold Time | 111 Days | 27 Days |
Enterprise Value | $205.46B | $7.32B |
Dividend Yield | 2.23% | 20.16% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
ZIM Integrated Shipping Services trades at $30.26, up 0.9% today and near its 52-week high of $30.96. The stock shows bullish technical momentum with strong moving average signals, though RSI indicators suggest potential overbought conditions. Fundamentally, Q2 2026 earnings beat expectations with $0.53 EPS versus -$0.02 expected, driven by 9% revenue growth to $1.8 billion. The company faces acquisition uncertainty with Hapag-Lloyd's $35 per share offer pending Israeli government approval.
Investment outlook remains mixed with strong operational performance offset by merger uncertainty. The stock trades at attractive valuations (P/S 0.57, P/B 0.94) but faces headwinds from declining 2026 profit margins (2.15% vs 6.94% in 2025). Analyst consensus leans cautious with 67% hold ratings, while technical indicators suggest near-term resistance at current levels. Key risks include government approval of acquisition and volatile shipping rates.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →